Project Grant HT94252310860
Award Date
9/1/23
Completion Date
8/31/25
Dollars Obligated
$3.1M
Federal Agency
Defense Health Agency
Awardee
Yale Univ (FL6GV84CKN57)
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Hamden, CT 06511, USA
Similar Awards
This Project Grant award from the Defense Health Agency, through the Military Medical Research and Development program (CFDA 12.420), provides $514,335 to Yale University to optimize adoptive cellular immunotherapy for rare melanomas. The award began on September 1, 2023 and is scheduled for completion on August 31, 2026. The research aims to transform health care for service members and the American public through innovative and impactful medical solutions, with a focus on developing treatments...
The Defense Health Agency has awarded a $1,674,999.00 Project Grant to Yale University under the Military Medical Research and Development program (CFDA 12.420). The grant is for the "PERTURBOMICS IDENTIFICATION OF CRITICAL GENETIC TARGETS IN NK CELLS FOR BREAST CANCER THERAPY" project, which will be conducted from September 1, 2023 to August 31, 2026. The funding will support basic, applied, and advanced biomedical research to transform healthcare for service members and the public...
The U.S. Defense Health Agency awarded a $1,213,276 Project Grant to Yale University under the Military Medical Research and Development program (CFDA 12.420). This 3-year grant, effective September 1, 2023 through August 31, 2026, will fund research on the role of vascular mimicry in the outgrowth of dormant melanoma micrometastases. The goal of this research is to transform health care for Service Members and the American public through innovative and impactful medical research on solutions...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,130,469 to Yale University to uncover the tumor-immune microenvironmental determinants of immunotherapy response in renal cell carcinoma through ex vivo patient-derived models. The research aims to transform health care for Service Members and the American public through innovative and impactful research investigating medical solutions for the battlefield....
This Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $1,158,989.00 to Yale University to conduct research on optimizing adoptive cellular immunotherapy for rare melanomas. The research project commenced on September 1, 2023 and is scheduled for completion by August 31, 2026. The key objectives of this grant-funded research are to advance innovative medical solutions for rare forms of melanoma that are difficult to...
The Department of the Army Medical Command awarded Yale University a $1,004,997 project grant under the Military Medical Research and Development program (CFDA 12.420). The grant will fund Yale University's pilot development of new forms of chimeric antigen receptor therapies for kidney cancer from August 15, 2021 to August 14, 2024. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public health care through...
The Defense Health Agency awarded Yale University a 3-year, USD 1,277,053 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to target the chromatin regulator WDR5 to treat breast cancer metastasis. The project aims to advance the understanding and development of novel therapeutic approaches for breast cancer, a leading cause of cancer-related deaths. As the prime awardee, Yale University will conduct the research, development, and testing activities...
The federal Project Grant award of $1,214,375.00 from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), is funding a research project led by Yale University. The project is investigating the use of decoy-resistant IL-18 and immune checkpoint inhibitors in preclinical murine and ex vivo patient-derived models of renal cell carcinoma. The award began on September 15, 2024 and is set to conclude on September 14, 2028. The Military Medical Research...
The U.S. Department of Defense's Defense Health Agency awarded a $1,235,447 Project Grant to Yale University on July 1, 2023. This 3-year grant, funded under the Military Medical Research and Development program (CFDA 12.420), will support research targeting the chromatin regulator WDR5 to treat breast cancer metastasis. The project aims to transform health care for service members and the general public through innovative and impactful biomedical research investigating medical solutions for the...
This $1,004,472 federal Project Grant award from the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420) supports Yale University's research on mast cell therapy for ovarian cancer. The award, which spans June 2025 to June 2029, will fund advanced biomedical research initiatives focused on transforming healthcare for military service members and the broader public. This project aims to explore innovative approaches to disease prevention,...